Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Equities researchers at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a note issued to investors on Thursday, August 20th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.19). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cocrystal Pharma’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.63) EPS.
Separately, Weiss Ratings cut shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Cocrystal Pharma Stock Performance
Shares of NASDAQ COCP opened at $1.11 on Monday. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.67. The business has a fifty day moving average of $1.01 and a two-hundred day moving average of $1.11. The stock has a market cap of $21.38 million, a PE ratio of -1.46 and a beta of 1.43.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million.
Hedge Funds Weigh In On Cocrystal Pharma
A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.72% of the company’s stock.
About Cocrystal Pharma
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
See Also
- Five stocks we like better than Cocrystal Pharma
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
